NeuCyte is a biotechnology company that leverages its proprietary SynFire® technology to advance drug discovery for central nervous system (CNS) disorders. This technology enables the generation of human induced pluripotent stem cell (iPSC)-derived neurons, creating a versatile in vitro platform that supports various applications, including target identification, efficacy testing, and neurotoxicity assessment. By utilizing patient-derived and genetically engineered neural cell types, NeuCyte develops unique cell-based assays that model neurological and neurodegenerative diseases, such as Alzheimer's disease, ALS, epilepsy, and Fragile X Syndrome. This innovative approach addresses the high attrition rates of CNS drugs in clinical development by providing biologically relevant models that better predict drug efficacy and safety.

NeuCyte's platform allows for the creation of complex human neural systems that can mimic the intricacies of the human brain. These systems facilitate advanced electrophysiological and morphological assessments, enabling researchers to evaluate the effects of compounds on neuronal health and function. By incorporating various neuronal subtypes and glial cells into three-dimensional brain assembloids, NeuCyte enhances the predictive power of its assays, making them more representative of human disease states. This capability not only aids in understanding the underlying biology of neurological disorders but also supports the identification of novel therapeutic targets, ultimately aiming to improve treatment options for patients suffering from these conditions.

United States

NeuCyte is a biotech company focused on CNS drug discovery. Its SynFire® technology uses human iPSC-derived neurons to identify drug targets, test efficacy, and safety of novel compounds for neurological disorders.

NeuCyte

Company Details